Carboplatin and bevacizumab for recurrent malignant glioma

Mrugala,Maciej M.; Crew,Laurie   K.; Fink,James   R.; Spence,Alexander   M.

doi:10.3892/ol.2012.839

Carboplatin and bevacizumab for recurrent malignant glioma

Authors:
- Maciej M. Mrugala
- Laurie K. Crew
- James R. Fink
- Alexander M. Spence
View Affiliations

Affiliations: Department of Neurology, University of Washington Medical School, Seattle, WA 98195, USA, Department of Neurosurgery, University of Washington Medical School, Seattle, WA 98195, USA, Department of Radiology, University of Washington Medical School, Seattle, WA 98195, USA, Department of Neurology, University of Washington Medical School, Seattle, WA 98195, USA
Published online on: August 1, 2012 https://doi.org/10.3892/ol.2012.839
Pages: 1082-1086

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Over 65,000 primary brain tumors are diagnosed annually in the US alone. Malignant gliomas represent more than one-third of such cases. Despite advances in neuroimaging, surgical techniques, radiotherapy and chemotherapy, the survival rate of this disease remains poor. The introduction of agents which disrupt the function of vascular endothelial growth factor (VEGF) and its receptors to glioma therapy has resulted in an unusually high percentage of patients experiencing radiographic responses. Bevacizumab, approved by the Food and Drug Administration for the treatment of recurrent glioblastoma in 2009, has changed the field of neuro-oncology. The drug has been utilized as a single agent and in combination with the classic cytotoxic agents typically applied in this setting. Numerous studies have reported high response rates and encouraging extensions of time-to-progression. The optimal schedule and combination of bevacizumab with alternative drugs has not been identified. The current study presents the results of a retrospective analysis of the combination therapy utilizing bevacizumab with the alkylating agent carboplatin in patients with recurrent malignant glioma.

View Figures

View References

1.	R StuppWP MasonMJ van den BentM WellerB FisherMJ TaphoornK BelangerRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med352987996200510.1056/NEJMoa04333015758009
2.	D FultonR UrtasunP ForsythPhase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant gliomaJ Neurooncol27149155199610.1007/BF001774788699237
3.	HS FriedmanWP PetrosAH FriedmanLJ SchaafT KerbyJ LawyerM ParryIrinotecan therapy in adults with recurrent or progressive malignant gliomaJ Clin Oncol1715161525199910334539
4.	WK YungRE AlbrightJ OlsonR FredericksK FinkMD PradosM BradaA phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBr J Cancer83588593200010.1054/bjoc.2000.131610944597
5.	RE WarnickMD PradosEE MackKL ChandlerF DozJE RabbittMK MalecA phase II study of intravenous carboplatin for the treatment of recurrent gliomasJ Neurooncol196974199410.1007/BF010510507815106
6.	Y WangD FeiM VanderlaanA SongBiological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis7335345200410.1007/s10456-004-8272-215886877
7.	V Stark-VanceBevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-OncologyNeuro-Oncol7abstract 3422005
8.	JJ VredenburghA DesjardinsJE Herndon IIJ MarcelloDA ReardonJA QuinnJN RichBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol2547224729200710.1200/JCO.2007.12.244017947719
9.	JJ VredenburghA DesjardinsJE Herndon IIJM DowellDA ReardonJA QuinnJN RichPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res1312531259200710.1158/1078-0432.CCR-06-230917317837
10.	HS FriedmanMD PradosPY WenT MikkelsenD SchiffLE AbreyWK YungBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol2747334740200910.1200/JCO.2008.19.872119720927
11.	TN KreislL KimK MooreP DuicC RoyceI StroudN GarrenPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol27740745200910.1200/JCO.2008.16.305519114704
12.	DA ReardonA DesjardinsJJ VredenburghS GururanganJH SampsonS SathornsumeteeRE McLendonMetronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II studyBr J Cancer10119861994200910.1038/sj.bjc.660541219920819
13.	S SathornsumeteeA DesjardinsJJ VredenburghRE McLendonJ MarcelloJE HerndonA MathePhase II trial of bevacizumab and erlotinib in patients with recurrent malignant gliomaNeuro Oncol1213001310201020716591
14.	A DesjardinsDA ReardonA CoanJ MarcelloJE Herndon IIL BaileyKB PetersBevacizumab and daily temozolomide for recurrent glioblastomaCancer11813021312201210.1002/cncr.2638121792866
15.	DA ReardonA DesjardinsKB PetersS GururanganJH SampsonRE McLendonJE Herndon IIPhase II study of carboplatin, irinotecan and bevacizumab for bevacizumab naïve, recurrent glioblastomaJ Neurooncol107155164201221986722
16.	AB FrancesconiS DupreM MatosD MartinBG HughesDK WyldJD LickliterCarboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiformeJ Clin Neurosci17970974201010.1016/j.jocn.2009.12.00920541421
17.	EM ThompsonE DosaDF KraemerEA NeuweltTreatment with bevacizumab plus carboplatin for recurrent malignant gliomaNeurosurgery678793201010.1227/01.NEU.0000370918.51053.BC20559095
18.	WK YungL MechtlerMJ GleasonIntravenous carboplatin for recurrent malignant glioma: a phase II studyJ Clin Oncol986086419911849986
19.	B JeremicD GrujicicS JevremovicB StanisavljevicL MilojevicL DjuricL MijatovicCarboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II studyJ Clin Oncol101074107719921318951
20.	RK JainNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience3075862200510.1126/science.110481915637262
21.	RK JainAntiangiogenic therapy for cancer: current and emerging conceptsOncology (Williston Park)19716200515934498
22.	AD NordenGS YoungK SetayeshA MuzikanskyR KlufasGL RossAS CiampaBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology70779787200810.1212/01.wnl.0000304121.57857.3818316689